Levente Ondi

Director of R. & D. at XiMo Hungary Ltd.

https://hu.linkedin.com/in/levente-ondi-2005931a

levente.ondi@ximo-inc.com

Experience

Director of R&D

XiMo Hungary Ltd.

December 2012 – Present (3 years 11 months)

Head of Chemistry Lab.

XiMo Hungary Ltd.

December 2010 – December 2012 (2 years 1 month)

Senior Research Scientist

Servier Research Institute of Medicinal Chemistry

January 2008 – December 2010 (3 years)

Head of R&D Laboratory II.

Chemical Future Pharma Ltd.

June 2005 – December 2007 (2 years 7 months)

Research Scientist

Chemical Future Pharma Ltd.

March 1999 – August 2001 (2 years 6 months)

Education

Swiss Federal Institute of Technology Lausanne

Ph.D., Organometallic Chemistry

2001 – 2005

Budapesti Mûszaki és Gazdaságtudományi Egyetem / Technical University of Budapest

Master of Science (M.Sc.), Chemical Engineering

1993 – 1999

Molybdenum- and tungsten-based olefin metathesis catalysts have demonstrated excellent results in the control of cis (Z-) selectivity as well as enantioselectivity. However, their air and moisture sensitivity, which requires the use of a glovebox, has prevented their more widespread use by organic chemists. Now we report on developed, preweighed Mo catalysts formulated in paraffin tablets. 

The significantly improved air stability, high homogeneity, and uniformity of the pellets allow researchers to carry out reactions on the bench avoiding the need of a glovebox.

The two different Mo-based complexes which were packed into tablets are XiMoPac-Mo001 (1) that can be used to achieve endo-selective enyne ring-closing metathesis (RCM) reactions, interalia; and XiMoPac-Mo003 (2) which was reported among the best catalysts to promote Z-selective cross-metathesis. 

For the evaluation of the wax-protected catalysts commonly used, highly reproducible robust model reactions were chosen: homo cross-metathesis (HCM) of functionalized (e.g., methyl 9-decenoate) and unfunctionalized (allylbenzene) terminal olefins, and ring closing metathesis (RCM) of diethyl diallylmalonate. The yields and conversions were comparable with those which can be achieved in glovebox with nonformulated catalysts. 

Exposure to air did not cause any significant reduction in conversion while the product selectivity (targeted product vs homologues derived from double bond isomerization) remained high. In contrast, exposure to air caused a measurable drop in the conversion with the nonprotected catalyst. Furthermore, the formulated catalysts remained unaffected even after 4 h of exposure to air, showing its enhanced air stability. 

In conclusion, these commercially available air-stable Mo-catalyst tablets allow the reactions to be accomplished using ordinary Schlenk techniques, and hence simplify catalyst handling in pilot laboratories and plants.

From Box to Bench: Air-Stable Molybdenum Catalyst Tablets for Everyday Use in Olefin Metathesis

Levente Ondi*†, Gergely M. Nagy†, Janos B. Czirok†, Agota Bucsai†, and Georg E. Frater‡

† XiMo Hungary Ltd., 7. Zahony Str., Budapest HU-1031, Hungary

‡ XiMo AG, 3. Altsagenstrasse, Horw/Luzern CH-6048, Switzerland

Org. Process Res. Dev., Article ASAP

DOI: 10.1021/acs.oprd.6b00161

*Telephone: (36) 1 580 2202; Fax: (36) 1-580 2201; E-mail: levente.ondi@ximo-inc.com.

http://pubs.acs.org/doi/abs/10.1021/acs.oprd.6b00161

Ximo Hungary Kft.  

Website

Directions

Chemical Plant

Address: Budapest, Záhony utca 7. D épület, 1031 Hungary

Prof. Dr. Georg Fráter

Chief Operating Officer

• Over 30 years experience in the Swiss chemical industry
• Over 20 years in the fragrance and flavor industry, five as Research Director for Givaudan
• Former President Swiss Chemical Society (SCS)
• Former Professor at the University of Zürich
• Current member of the board of Thales Nano

Education: Ph.D. University of Zurich; M.Sc. University of Zurich

//////////

Narendra Ambhaikar

Senior Director, Teva Pharmaceuticals

LINKS

https://in.linkedin.com/in/narendra-ambhaikar-70597a

Experience

Head - Technical Services, TAPI India

Teva Pharmaceuticals

December 2014 – Present (1 year 11 months)Greater Noida

New and existing Generic APIs: new products & their process evaluations, technology transfers and commercial production

Director, Head - R&D (APIs and Intermediates)

Piramal Enterprises

August 2013 – November 2014 (1 year 4 months)Chennai

Led synthetic and analytical teams in the CRAMS business of Piramal. Enabled teams to generate innovative ideas for the business and deliver molecules (ranging from kilos to metric ton scale) via cost effective and green processes.

NARENDRA AMBHAIKAR, DHILEEP KRISHNAMURTHY
Piramal Enterprises Limited

Group Leader, Process Research & Development

Dr. Reddy's Laboratories

June 2010 – August 2012 (2 years 3 months)Hyderabad Area, India

Route scouting and process development of NCEs, Intermediates and Generic APIs

Scientist I, then Scientist II - Chemical Development

Vertex Pharmaceuticals (San Diego)

December 2005 – May 2010 (4 years 6 months)Greater San Diego Area, U.S.A.

Process chemistry (R&D) of clinical candidates and intermediates for HCV and Cystic Fibrosis. Key Publication: Organic Process Research and Development 2015, 19(1), 270–283.

Post-Doctoral Scholar (with Prof. Phil Baran)

The Scripps Research Institute (La Jolla)

January 2004 – January 2006 (2 years 1 month)Greater San Diego Area, U.S.A.

Total Synthesis of Complex Natural Products: Indole Alkaloids Stephacidins and Avrainvillamide involving New Synthetic Transformations. Key Publications: 1) Journal of the American Chemical Society 2006, 128(26), 8678-8693. 2) Angewandte Chemie International Edition 2005, 44(4), 606-609.

Ph.D.

Emory University, U.S.A.

August 1999 – September 2003 (4 years 2 months)Greater Atlanta Area

Research Associate, API Scale Up

RPG Life Sciences

1996 – 1997 (1 year)Mumbai Area

Summer Trainee

Sanofi (formerly Hoechst)

May 1995 – June 1995 (2 months)Mumbai

Pilot plant and production, including formulation manufacturing

Education

Emory University (U.S.A.)

Ph.D., Organic Chemistry (Adviser: Prof. Dennis Liotta)

1999 – 2003

Doctoral Work in Mechanism Driven New Reactions Employing Oxazolidinone and Thiazolidethione Chiral Auxiliaries. Key Publication: Journal of the American Chemical Society, 2003, 125 (13), 3690–3691.

U.D.C.T., Mumbai, India

M.Sc.Tech., Pharmaceutical Chemistry

1997 – 1999

Investigated applications of chemistry and chemical engineering in the manufacturing of Pharmaceuticals and Fine Chemicals

U.D.C.T., Mumbai, India

B.Sc.Tech., Pharmaceuticals and Fine Chemicals

1993 – 1996

St. Xavier's College, Mumbai, India

B.Sc., Chemistry

1990 – 1993

Sir Cowasjee Jehangir High School

SSC

Baran Group Members

Process research as a tool to attain Green Chemistry in the Pharmaceutical Industry

NARENDRA AMBHAIKAR, DHILEEP KRISHNAMURTHY
Piramal Enterprises Limited, Ennore Express Highway, Ennore, Chennai, Tamilnadu 600057, India

KEYWORDS: R&D, API, Green Chemistry by Design (GCbD), Process Research, synthesis, manufacture
ABSTRACT: The pharmaceutical manufacturing industry faces the challenging task of operating sustainably with minimal safety, cost and environmental impact. While the ‘D’ part or process development in R&D is a very critical activity toward the scale-up of Active Pharmaceutical Ingredients (APIs) and intermediates, the ‘R’ part (process research) can also profoundly influence the API manufacturing industry; and it can be a deciding factor in the greenness of the process. The concept of Green Chemistry by Design (GCbD) enables one to understand the relationship between process research, sustainability and economics with respect to API. Proactively designing synthetic routes by recognizing criteria such as safety, environmental, legal, economics, control as well as throughput is an important step in the selection of a practical synthetic route. More often than not, a cost effective process is a green process. Existing and emerging scientific tools and technologies when identified and applied appropriately contribute to greener and more economical routes on large scale. Additionally, with the wealth of new reactions that continue to be discovered in the academic world, the field of process research toward organic compounds continues to remain dynamic, thus providing opportunities to develop green synthetic routes.

INTRODUCTION
The pharmaceutical industry has continued to go through major changes since its inception. More drugs than before continue to be discovered, developed and launched, benefiting the patient and thus reducing the burden of disease. While the advantages of this established and yet growing industry are undeniably obvious, the challenges that it continues to face are unique. Sustainable and efficient production of chemicals with the least impact on the environment remains a difficult task, given the various hurdles faced by the industry such as cost-effectiveness, regulatory, legal, robustness, “greenness” and safety. These changing times have stirred the industrial and academic scientific community to work toward developing better reactions and processes. Until recently, the development of green and environmentally friendly processes remained confined mostly to the innovator and generic pharmaceutical companies; while today the growing API business demands the same in pursuit of sustainability, cost-effectiveness and value addition for its customers.

A sustainable process for an intermediate or an API stems from an innovative, well-thought out and planned process R&D work based on the principles of Green Chemistry. The term E (environmental) factor, defined as the kilograms of waste per kilogram of product, was introduced as a measure of the environmental effect of a manufacturing process in various chemical businesses (1). While there are several other measurable terms and concepts in Green Chemistry, the E-factor remains widely used and represents the actual amount of waste produced in a chemical process (2). Compared to the other segments of the industry, the pharmaceutical and fine chemical industry generates significant waste per kilogram of product, mainly due to the complexity of the synthetic processes involved thus leading to higher E-factors. However, with the introduction of...In order to continue reading this article please register to our website – registration is for free and no fees will be applied afterwards to download contents.

 Download PDF

//////////////